FDA Holds Back MDMA Psychedelic Therapy Over Safety, Efficacy Concerns | Amznusa.com

Lykos, the developer of the MDMA-assisted therapy for PTSD, called the FDA’s request for more phase 3 research “deeply disappointing.” Lykos, the developer of the MDMA-assisted therapy for PTSD, called the FDA’s request for more phase 3 research “deeply disappointing.”